[go: up one dir, main page]

WO2008114505A1 - Inhibiteur d'eg5 et agent destinés au traitement d'un trouble de la prolifération cellulaire les contenant - Google Patents

Inhibiteur d'eg5 et agent destinés au traitement d'un trouble de la prolifération cellulaire les contenant Download PDF

Info

Publication number
WO2008114505A1
WO2008114505A1 PCT/JP2008/000617 JP2008000617W WO2008114505A1 WO 2008114505 A1 WO2008114505 A1 WO 2008114505A1 JP 2008000617 W JP2008000617 W JP 2008000617W WO 2008114505 A1 WO2008114505 A1 WO 2008114505A1
Authority
WO
WIPO (PCT)
Prior art keywords
group
agent
treatment
cell proliferative
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2008/000617
Other languages
English (en)
Japanese (ja)
Inventor
Akira Asai
Junichi Sawada
Kenji Matsuno
Naohisa Ogo
Nobutaka Fujii
Shinya Oishi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PHARMA IP Ltd LIABILITY INTERMEDIARY Corp
Original Assignee
PHARMA IP Ltd LIABILITY INTERMEDIARY Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by PHARMA IP Ltd LIABILITY INTERMEDIARY Corp filed Critical PHARMA IP Ltd LIABILITY INTERMEDIARY Corp
Priority to JP2009505077A priority Critical patent/JPWO2008114505A1/ja
Publication of WO2008114505A1 publication Critical patent/WO2008114505A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne un inhibiteur d'Eg5 contenant un dérivé de cystéine représenté par la formule (I) ci-dessous ou un sel pharmacologiquement acceptable de celui-ci en tant qu'un ingrédient actif. La présente invention concerne également un agent destiné au traitement des troubles de la prolifération cellulaire. [formule chimique 1] (I) (Dans la formula, Ar représente un groupe aryle substitué ou non substitué ou un groupe hétérocyclique aromatique substitué ou non substitué ; R1 représente un atome d'hydrogène ou un groupe de protection d'un groupe amino ; et R2 et représente un groupe hydroxy, un groupe alcoxy, un groupe amino, un groupe -NH(CH2)2O(CH2)2NH2 ou équivalents. A cet égard, lorsque Ar est un groupe phényle, R2 est un groupe autre qu'un groupe hydroxy.)
PCT/JP2008/000617 2007-03-16 2008-03-17 Inhibiteur d'eg5 et agent destinés au traitement d'un trouble de la prolifération cellulaire les contenant Ceased WO2008114505A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2009505077A JPWO2008114505A1 (ja) 2007-03-16 2008-03-17 Ｅｇ５阻害剤および該化合物を含有してなる細胞増殖性疾患治療薬

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007069487 2007-03-16
JP2007-069487 2007-03-16

Publications (1)

Publication Number Publication Date
WO2008114505A1 true WO2008114505A1 (fr) 2008-09-25

Family

ID=39765623

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/000617 Ceased WO2008114505A1 (fr) 2007-03-16 2008-03-17 Inhibiteur d'eg5 et agent destinés au traitement d'un trouble de la prolifération cellulaire les contenant

Country Status (2)

Country Link
JP (1) JPWO2008114505A1 (fr)
WO (1) WO2008114505A1 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8349899B1 (en) 2008-12-03 2013-01-08 Arrowhead Center, Inc. Selective inhibitors of EG5 motors and methods of use
CN103740648A (zh) * 2013-11-20 2014-04-23 成都正能生物技术有限责任公司 一种纺锤体驱动蛋白(Eg5)单克隆抗体及分泌该单克隆抗体的杂交瘤细胞株
US8765817B1 (en) 2008-12-03 2014-07-01 Arrowhead Center, Inc. Selective inhibitors of EG5 motors and methods of use
US9902690B2 (en) 2013-12-27 2018-02-27 Novus International, Inc. Ethoxylated surfactants
US10584306B2 (en) 2017-08-11 2020-03-10 Board Of Regents Of The University Of Oklahoma Surfactant microemulsions

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007104011A2 (fr) * 2006-03-08 2007-09-13 University Of Maryland, Baltimore Inhibition de protrusion de microtubule dans des cellules cancereuses

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007104011A2 (fr) * 2006-03-08 2007-09-13 University Of Maryland, Baltimore Inhibition de protrusion de microtubule dans des cellules cancereuses

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DEBONIS S. ET AL.: "STRUCTURE-ACTIVITY RELATIONSHIP OF S-TRITYL-L-CYSTEINE ANALOGUES AS INHIBITORS OF THE HUMAN MITOTIC KINESIN EG5", J. MED. CHEM., vol. 51, no. 5, 13 March 2008 (2008-03-13), pages 1115 - 1125 *
KESSEL D. ET AL.: "EFFECTS OF S-(TRITYL)-L-CYSTEINE AND ITS ANALOGS ON CELL SURFACE PROPERTIES OF LEUKEMIA L1210 CELLS", BIOCHEM. PHARMACOL., vol. 25, no. 16, 1976, pages 1893 - 1897, XP023729552, DOI: doi:10.1016/0006-2952(76)90195-7 *
OGO N. ET AL.: "SYNTHESIS AND BIOLOGICAL EVALUATION OF L-CYSTEINE DERIVATIVES AS MITOTIC KINESIN EG5 INHIBITORS", BIOORG. MED. CHEM. LETT., vol. 17, no. 14, 15 July 2007 (2007-07-15), pages 3921 - 3924, XP022119981 *
ZEE-CHENG K.Y. ET AL.: "EXPERIMENTAL ANTILEUKEMIC AGENTS. PREPARATION AND STRUCTURE-ACTIVITY STUDY OF S-TRITYLCYSTEINE AND RELATED COMPOUNDS", J. MED. CHEM., vol. 13, no. 3, 1970, pages 414 - 418, XP002919020 *
ZEE-CHENG K.Y. ET AL.: "STRUCTURAL MODIFICATION OF S-TRITYL-L-CYSTEINE. PREPARATION OF SOME S-(SUBSTITUTED TRITYL)-L-CYSTEINES AND DIPEPTIDES OF TRITYL-L-CYSTEINE", J. MED. CHEM., vol. 15, no. 1, 1972, pages 13 - 16, XP002398931 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8349899B1 (en) 2008-12-03 2013-01-08 Arrowhead Center, Inc. Selective inhibitors of EG5 motors and methods of use
US8765817B1 (en) 2008-12-03 2014-07-01 Arrowhead Center, Inc. Selective inhibitors of EG5 motors and methods of use
CN103740648A (zh) * 2013-11-20 2014-04-23 成都正能生物技术有限责任公司 一种纺锤体驱动蛋白(Eg5)单克隆抗体及分泌该单克隆抗体的杂交瘤细胞株
CN103740648B (zh) * 2013-11-20 2016-08-31 成都汇瑞新元生物科技有限责任公司 一种纺锤体驱动蛋白(Eg5)单克隆抗体及分泌该单克隆抗体的杂交瘤细胞株
US9902690B2 (en) 2013-12-27 2018-02-27 Novus International, Inc. Ethoxylated surfactants
US10584306B2 (en) 2017-08-11 2020-03-10 Board Of Regents Of The University Of Oklahoma Surfactant microemulsions

Also Published As

Publication number Publication date
JPWO2008114505A1 (ja) 2010-07-01

Similar Documents

Publication Publication Date Title
WO2008114812A1 (fr) Inhibiteur de jak
WO2008126901A1 (fr) Composé hétérocyclique contenant de l'azote et composition pharmaceutique le contenant
WO2009069736A1 (fr) Composé azoté
WO2008087933A1 (fr) Nouveau dérivé d'indole ayant une activité inhibitrice sur la iκb kinase β
TW200616994A (en) Novel thiophene derivatives
WO2005097129A3 (fr) Compose de 6-azaindole
MY146532A (en) Thiazole derivative
AU2009258496A8 (en) Sulfur-containing heterocyclic derivative having beta-secretase-inhibiting activity
WO2008108386A1 (fr) Composition pharmaceutique
WO2007082808A3 (fr) Thiazoles en tant qu'inhibiteurs de 11 beta-hsd1
WO2007122634A3 (fr) Inhibiteurs de kinase
WO2007095174A3 (fr) derives d'acides biliaires en tant que ligands de FXR pour la prevention ou le traitement de maladies ou d'etats induits par FXR
TW200800937A (en) Heterocyclic compound
MX2009005691A (es) Inhibidores de la enzima de diacilglicerol o-acilotransferasa tipo i.
WO2008123017A1 (fr) Nouveau derivé de diamide
TW200612913A (en) Substituted indolyl alkyl amino derivatives as novel inhibitors of histone deacetylase
WO2005012269A8 (fr) Nouveau compose azole
GEP20094605B (en) Pyrazole derivatives, compositions containing such compounds and methods of use thereof
WO2005095395A3 (fr) Derives de tetrahydronaphtyridine et procede d’elaboration desdits derives
WO2008108378A3 (fr) Dérivé bicyclique d'oxomorpholine
GB2442148A (en) FK 228 derivates as HDAC inhibitors
TW200734322A (en) Indole derivatives exhibiting PGD2 receptor antagonism
WO2007020213A3 (fr) Derives de thiazolylpiperidines
MX2010001566A (es) Derivado de aminopirazolamida.
TW200745063A (en) Triazolone derivatives

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08720502

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2009505077

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08720502

Country of ref document: EP

Kind code of ref document: A1